Baystreet Staff -

Revance Therapeutics, Inc. (RVNC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings


NEW YORK, NY / ACCESSWIRE / September 27, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC). Investors who purchased Revance securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:

The investigation concerns whether Revance has violated federal securities laws.

Investigation Details:

On September 19, 2023, in an Investor Day presentation, the Company announced a new strategy for its cosmetic dermal filler Daxxify, revealing a drop in price that the Company expects will "accelerate market expansion" as it attempts to increase sales. On this news, Revance's stock price fell $2.89 per share, or 17.31%, to close at $13.81 per share on September 19, 2023.

What's Next?

If you are aware of any facts relating to this investigation or purchased Revance securities, you can assist this investigation by visiting the firm's site: You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on